Gwenn Hansen - Aug 9, 2022 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Scientific Officer
Signature
/s/ Christine Ring, as Attorney-in-Fact for Gwenn Hansen
Stock symbol
NRIX
Transactions as of
Aug 9, 2022
Transactions value $
$0
Form type
4
Date filed
8/10/2022, 04:15 PM
Previous filing
Aug 2, 2022
Next filing
Nov 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Award $0 +60.3K $0.00 60.3K Aug 9, 2022 Common Stock 60.3K $18.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/48 of the total shares monthly beginning September 9, 2022 until the option is fully vested on August 9, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.